Pharmacology Quiz: Arni And Sglt2 Inhibitors In Hf
20 questions · exam conditions
0:00
Arni And Sglt2 Inhibitors In HfQuestion 1 of 20

A 72-year-old female with HFrEF, type 2 diabetes, and CKD stage 3 (eGFR 45 mL/min/1.73m²) is treated with sacubitril/valsartan, bisoprolol, and spironolactone. Her cardiologist adds dapagliflozin 10 mg daily. Two weeks later, her eGFR has decreased to 38 mL/min/1.73m².

What is the most appropriate interpretation and action regarding the change in her renal function?

This represents significant nephrotoxicity; dapagliflozin should be discontinued immediately to prevent irreversible kidney damage.
The drop in eGFR is an expected hemodynamic effect due to tubuloglomerular feedback; continue dapagliflozin and monitor renal function.
This is likely due to a drug interaction with spironolactone causing hyperkalemic nephropathy; dapagliflozin should be held and spironolactone dose reduced.
The patient is likely volume depleted; dapagliflozin should be continued, but the dose of spironolactone should be increased to preserve renal perfusion.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Arni And Sglt2 Inhibitors In Hf

Practice Arni And Sglt2 Inhibitors In Hf in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Arni And Sglt2 Inhibitors In Hf, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 72-year-old female with HFrEF, type 2 diabetes, and CKD stage 3 (eGFR 45 mL/min/1.73m²) is treated with sacubitril/valsartan, bisoprolol, and spironolactone. Her cardiologist adds dapagliflozin 10 mg daily. Two weeks later, her eGFR has decreased to 38 mL/min/1.73m².

What is the most appropriate interpretation and action regarding the change in her renal function?

  1. This represents significant nephrotoxicity; dapagliflozin should be discontinued immediately to prevent irreversible kidney damage.
  2. The drop in eGFR is an expected hemodynamic effect due to tubuloglomerular feedback; continue dapagliflozin and monitor renal function. (correct answer)
  3. This is likely due to a drug interaction with spironolactone causing hyperkalemic nephropathy; dapagliflozin should be held and spironolactone dose reduced.
  4. The patient is likely volume depleted; dapagliflozin should be continued, but the dose of spironolactone should be increased to preserve renal perfusion.
Explanation: The correct answer is B. Initiation of an SGLT2 inhibitor frequently causes a small, acute, and reversible dip in eGFR. This is a physiological response to increased sodium delivery to the macula densa, which activates tubuloglomerular feedback, leading to afferent arteriolar vasoconstriction and a reduction in intraglomerular pressure. This hemodynamic effect is believed to contribute to the long-term renoprotective benefits of the drug class. A drop of this magnitude (~15%) is typically expected and managed by continuing the drug with ongoing monitoring, as long as the patient is hemodynamically stable. A is incorrect because this is an expected, not a toxic, effect. C is incorrect as this is not a feature of a dapagliflozin-spironolactone interaction. D is incorrect because if volume depletion were the primary concern, increasing a diuretic (spironolactone) would be inappropriate.

Question 2

A 70-year-old patient with HFrEF and T2DM is managed with metformin, sacubitril/valsartan, and carvedilol. An SGLT2 inhibitor is added. The patient is counseled on the risk of euglycemic diabetic ketoacidosis (DKA). Which of the following situations would most significantly increase this patient's risk of developing euglycemic DKA?

  1. Experiencing a period of acute illness, such as influenza with poor oral intake. (correct answer)
  2. Consuming a high-carbohydrate meal before a strenuous workout.
  3. Missing a single dose of their metformin.
  4. A slight, asymptomatic increase in serum creatinine.
Explanation: When you encounter SGLT2 inhibitor questions, focus on understanding euglycemic DKA—a serious condition where ketoacidosis occurs without significantly elevated glucose levels. SGLT2 inhibitors increase ketone production while lowering glucose, creating this dangerous scenario. Acute illness with poor oral intake (A) creates the perfect storm for euglycemic DKA. During illness, your body releases stress hormones that promote ketone production while simultaneously reducing insulin effectiveness. Poor oral intake means inadequate carbohydrate consumption, forcing the body to break down fat for energy—further increasing ketones. The SGLT2 inhibitor compounds this by continuing to lower glucose levels while promoting ketogenesis. This combination of metabolic stress, reduced food intake, and ongoing SGLT2 inhibition dramatically increases euglycemic DKA risk. A high-carbohydrate meal before exercise (B) would actually be protective, as carbohydrates provide glucose and reduce the need for fat breakdown. Missing one metformin dose (C) has minimal acute impact since metformin doesn't directly affect ketone metabolism and has a long half-life. A slight creatinine increase (D) might warrant monitoring but doesn't acutely precipitate ketoacidosis—SGLT2 inhibitors often cause mild, reversible creatinine elevations. Remember this pattern: SGLT2 inhibitor + any condition that promotes ketone production (illness, fasting, dehydration, surgery) = high euglycemic DKA risk. Always counsel patients to temporarily discontinue SGLT2 inhibitors during acute illness, especially with poor oral intake, vomiting, or dehydration.

Question 3

The landmark PARADIGM-HF trial demonstrated the superiority of sacubitril/valsartan over enalapril in patients with HFrEF. The primary endpoint was a composite of death from cardiovascular causes or first hospitalization for worsening heart failure. What is the accepted pharmacological explanation for this superior efficacy?

  1. The simultaneous inhibition of neprilysin and blockade of the RAAS provides benefits from natriuretic peptide enhancement that are not achieved by RAAS inhibition alone. (correct answer)
  2. Sacubitril/valsartan provides more potent and complete blockade of the AT1 receptor compared to enalapril's inhibition of ACE.
  3. Sacubitril/valsartan causes a greater reduction in heart rate and blood pressure, which are the primary drivers of improved outcomes.
  4. Enalapril has a higher incidence of cough, leading to poor adherence and consequently worse outcomes in the comparator arm.
Explanation: When you encounter questions about heart failure medications, focus on understanding the specific mechanisms of action and how they translate to clinical benefits. The PARADIGM-HF trial is a landmark study that changed heart failure treatment guidelines. Sacubitril/valsartan (Entresto) is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI). The key to its superior efficacy lies in its dual mechanism: it blocks the renin-angiotensin-aldosterone system (RAAS) through valsartan's AT1 receptor antagonism while simultaneously inhibiting neprilysin through sacubitril. Neprilysin is an enzyme that breaks down beneficial natriuretic peptides (BNP, ANP). By blocking neprilysin, sacubitril allows these peptides to accumulate, promoting vasodilation, natriuresis, and diuresis. This dual approach provides the proven benefits of RAAS blockade plus additional cardiovascular protection from enhanced natriuretic peptide activity that ACE inhibitors alone cannot achieve. Option B is incorrect because valsartan doesn't provide "more potent" AT1 blockade than enalapril's ACE inhibition—these are simply different mechanisms of RAAS interruption with similar efficacy profiles. Option C misses the primary mechanism; while hemodynamic effects occur, the superior outcomes stem from the neprilysin inhibition component, not greater blood pressure reduction. Option D incorrectly attributes the difference to adherence issues with enalapril's cough side effect, but this wasn't the explanation for PARADIGM-HF's results. Remember: ARNI represents a paradigm shift because it's the first medication to simultaneously enhance a protective pathway (natriuretic peptides) while blocking a harmful one (RAAS).

Question 4

A 65-year-old patient with HFrEF is stable on enalapril 10 mg twice daily. According to clinical guidelines and evidence from pivotal trials, what is the primary rationale for switching this patient to a target dose of sacubitril/valsartan?

  1. To achieve a further reduction in morbidity and mortality beyond that provided by the ACE inhibitor. (correct answer)
  2. To significantly reduce the incidence of the dry cough associated with enalapril therapy.
  3. To simplify the medication regimen, as sacubitril/valsartan has a once-daily dosing option.
  4. To mitigate the risk of hyperkalemia, as sacubitril/valsartan is less likely to raise potassium than enalapril.
Explanation: When you encounter questions about switching established heart failure therapies, focus on the primary clinical benefit that drove the change in treatment guidelines, not secondary advantages or misconceptions about the newer drug. Sacubitril/valsartan (Entresto) represents a major advancement in heart failure with reduced ejection fraction (HFrEF) treatment. The landmark PARADIGM-HF trial demonstrated that patients switched from ACE inhibitors to sacubitril/valsartan experienced a significant 20% reduction in cardiovascular death and heart failure hospitalization compared to continuing enalapril. This dual mechanism drug combines neprilysin inhibition (which preserves beneficial natriuretic peptides) with ARB activity, providing superior outcomes beyond what ACE inhibitors alone can achieve. Answer A is correct because the primary evidence-based rationale for switching stable HFrEF patients is to achieve additional morbidity and mortality reduction beyond ACE inhibitor therapy. Answer B is incorrect because while sacubitril/valsartan may reduce dry cough (since it contains an ARB, not an ACE inhibitor), this wasn't the primary reason for the guideline recommendation and isn't the main clinical benefit. Answer C is wrong because sacubitril/valsartan is actually dosed twice daily, not once daily, so it doesn't simplify the regimen. Answer D is incorrect because sacubitril/valsartan can still cause hyperkalemia due to its ARB component blocking angiotensin II receptors, similar to ACE inhibitors' potassium-raising effects. Remember: When newer heart failure medications receive Class I guideline recommendations, it's typically because they demonstrated superior hard endpoints (death/hospitalization) in major trials, not just symptom improvement or convenience factors.

Question 5

A patient with a history of idiopathic angioedema (not related to any medication) is being considered for HFrEF therapy. Which statement regarding the use of sacubitril/valsartan in this patient is most accurate?

  1. The medication is strictly contraindicated due to any history of angioedema, regardless of the cause.
  2. The medication can be initiated, as the contraindication applies only to angioedema specifically caused by prior ACE inhibitor or ARB therapy.
  3. The medication can be used, but only if the patient is pre-treated with an H1-receptor antagonist to prevent a reaction.
  4. The medication should be avoided, as neprilysin inhibition can exacerbate any predisposition to angioedema by increasing bradykinin levels. (correct answer)
Explanation: The correct answer is D. While the absolute contraindication for sacubitril/valsartan is a history of angioedema related to previous ACE inhibitor or ARB therapy, caution is strongly advised in patients with any history of angioedema. Neprilysin inhibition increases levels of bradykinin, a key mediator of angioedema. In a patient with a known predisposition to angioedema (even idiopathic), using a drug that increases bradykinin levels poses a significant risk of triggering an episode. Therefore, it should generally be avoided. A is too absolute; the formal contraindication is specific to ACEi/ARB-related angioedema. B is a dangerous misinterpretation of the guidelines; while not an absolute contraindication, the risk is high and it should be used with extreme caution, if at all. C is incorrect as pre-treatment is not a standard or validated approach to mitigate this risk.

Question 6

In the context of myocardial energetics, a key proposed benefit of SGLT2 inhibitors in heart failure is the shift of substrate utilization in the heart. This involves a relative increase in the oxidation of which fuel source by cardiomyocytes?

  1. Glycogen stores
  2. Long-chain fatty acids
  3. Lactate
  4. Ketone bodies (correct answer)
Explanation: The correct answer is D. The failing heart is often described as an 'engine out of fuel,' with impaired metabolism of its usual primary fuel, fatty acids. SGLT2 inhibitors induce a mild, chronic state of hyperketonemia. Ketone bodies (like beta-hydroxybutyrate) are a highly efficient fuel source for the heart, producing more ATP per unit of oxygen consumed compared to fatty acids. It is hypothesized that this metabolic shift to ketone oxidation improves myocardial efficiency and function, contributing to the cardiovascular benefits of the drug class. A, B, and C are all cardiac fuel sources, but the specific shift promoted by SGLT2 inhibitors that is thought to be beneficial is away from fatty acids (B) and towards ketones (D).

Question 7

A patient taking sacubitril/valsartan and spironolactone for HFrEF is prescribed ibuprofen for osteoarthritis pain. Which of the following potential complications is of greatest concern with this combination?

  1. Acute worsening of heart failure due to the sodium-retaining effects of the NSAID.
  2. Severe hypotension due to synergistic vasodilatory effects of the ARNI and the NSAID.
  3. Acute kidney injury and severe hyperkalemia from the 'triple whammy' effect on renal function. (correct answer)
  4. Increased risk of gastrointestinal bleeding due to an interaction between spironolactone and ibuprofen.
Explanation: The correct answer is C. The combination of a RAAS inhibitor (like an ARNI), a diuretic (spironolactone acts as a potassium-sparing diuretic), and an NSAID is known as the 'triple whammy.' RAAS inhibitors dilate the efferent arteriole, diuretics can cause volume depletion, and NSAIDs constrict the afferent arteriole by inhibiting prostaglandin synthesis. This combination severely compromises renal perfusion and glomerular filtration, leading to a high risk of acute kidney injury (AKI). Furthermore, all three medications can independently increase serum potassium, making the risk of severe hyperkalemia very high. A is a valid concern but less acute and severe than the risk of AKI. B is incorrect as NSAIDs do not cause vasodilation; they can actually increase blood pressure. D is incorrect as there is no specific interaction between spironolactone and ibuprofen that increases GI bleeding risk beyond the baseline risk from the NSAID itself.

Question 8

A 62-year-old woman with a history of heart failure with preserved ejection fraction (HFpEF, LVEF 55%), obesity, and hypertension is being evaluated for additional therapy. Based on recent large-scale clinical trials, which agent would be most appropriate to add to her regimen to reduce the risk of heart failure hospitalizations, and what is the key feature of its evidence base?

  1. Sacubitril/valsartan, which showed a significant reduction in mortality and hospitalization across the full spectrum of LVEF in the PARAGON-HF trial.
  2. Empagliflozin, which demonstrated a significant reduction in a composite of cardiovascular death or HF hospitalization in patients with HFpEF, including those without diabetes. (correct answer)
  3. Spironolactone, which is the only MRA proven to reduce mortality in a dedicated HFpEF trial (TOPCAT) among all enrolled geographic regions.
  4. Digoxin, which has been shown to improve quality of life and reduce hospitalizations in HFpEF by enhancing diastolic relaxation.
Explanation: The correct answer is B. Large clinical trials like EMPEROR-Preserved (with empagliflozin) and DELIVER (with dapagliflozin) have demonstrated that SGLT2 inhibitors significantly reduce the risk of the composite primary endpoint of cardiovascular death or hospitalization for heart failure in patients with HFpEF, irrespective of their diabetes status. This has established SGLT2 inhibitors as a foundational therapy for HFpEF. A is incorrect because the PARAGON-HF trial of sacubitril/valsartan in HFpEF narrowly missed its primary endpoint, though subgroup analyses suggested potential benefit in women and those with lower-range LVEF. It did not show benefit across the full spectrum. C is incorrect because the TOPCAT trial of spironolactone in HFpEF had inconsistent results, with benefits seen primarily in the Americas but not in Russia/Georgia, raising questions about its overall efficacy in the broad HFpEF population. D is incorrect as digoxin has not been shown to have a mortality benefit or to consistently reduce hospitalizations in HFpEF and its mechanism is primarily inotropic, not related to diastolic relaxation.

Question 9

A patient is prescribed sacubitril as a monotherapy for hypertension without a concurrent angiotensin receptor blocker (ARB) or ACE inhibitor. Which of the following outcomes is most likely to occur as a result of inhibiting neprilysin alone?

  1. A profound and sustained decrease in blood pressure due to unopposed accumulation of natriuretic peptides without any significant adverse effects.
  2. A blunted effect on blood pressure due to compensatory activation of the renin-angiotensin-aldosterone system (RAAS) that is not blocked. (correct answer)
  3. Selective reduction in cardiac preload with no effect on afterload, leading to an isolated improvement in diastolic function.
  4. Severe hyperkalemia resulting from the direct inhibition of potassium channels in the renal collecting duct by sacubitril's active metabolite.
Explanation: The correct answer is B. Neprilysin degrades not only natriuretic peptides but also angiotensin II. Inhibiting neprilysin with sacubitril alone would lead to an accumulation of angiotensin II. This would cause potent vasoconstriction and aldosterone release, counteracting the beneficial vasodilatory and natriuretic effects of the accumulated natriuretic peptides. This is precisely why a neprilysin inhibitor must be co-administered with a RAAS blocker (specifically an ARB, not an ACEI due to angioedema risk). The ARB blocks the effects of the increased angiotensin II, allowing the benefits of natriuretic peptide enhancement to prevail. A is incorrect because the effect would be blunted, not profound. C is incorrect as the peptide effects would influence both preload and afterload, but the main issue is the counter-regulatory RAAS activation. D is incorrect as sacubitril does not directly cause hyperkalemia via this mechanism; hyperkalemia with ARNIs is related to the ARB component's effect on aldosterone.

Question 10

A 68-year-old male with a history of hypertension and HFrEF (LVEF 30%) is managed in a cardiology clinic. His current medications include lisinopril 20 mg daily, carvedilol 25 mg twice daily, and furosemide 40 mg daily. He remains symptomatic (NYHA Class II). The decision is made to discontinue lisinopril and initiate sacubitril/valsartan.

Which of the following is the most critical step to ensure patient safety during this medication transition, and what is the underlying pharmacological reason for this precaution?

  1. Administer the first dose of sacubitril/valsartan with the last dose of lisinopril to ensure continuous RAAS blockade and prevent rebound hypertension.
  2. Initiate sacubitril/valsartan at least 36 hours after the last dose of lisinopril to allow for clearance of the ACE inhibitor and reduce the risk of angioedema. (correct answer)
  3. Start a low-dose ARB for 24 hours as a bridge therapy between stopping lisinopril and starting sacubitril/valsartan to prevent acute decompensation.
  4. Check plasma renin activity before starting sacubitril/valsartan to ensure the RAAS is not overly suppressed, which would increase the risk of severe hypotension.
Explanation: The correct answer is B. Concurrent use of an ACE inhibitor (like lisinopril) and a neprilysin inhibitor (sacubitril) is contraindicated due to a significantly increased risk of life-threatening angioedema. Neprilysin breaks down bradykinin, while ACE inhibitors prevent its breakdown. The dual inhibition leads to excessive bradykinin accumulation. A 36-hour washout period is mandatory when switching from an ACE inhibitor to an ARNI to allow the ACE inhibitor to be cleared from the system. A is incorrect because co-administration is dangerous and specifically contraindicated. C is incorrect because a bridge therapy is not required, and the ARB component is already part of the ARNI. The key is the washout period, not adding another drug. D is incorrect because while RAAS status is important for blood pressure, measuring plasma renin activity is not a standard or necessary step, and the primary safety concern during the switch is angioedema, not hypotension.

Question 11

A 68-year-old male with a history of hypertension and HFrEF (LVEF 30%) is managed in a cardiology clinic. His current medications include lisinopril 20 mg daily, carvedilol 25 mg twice daily, and furosemide 40 mg daily. He remains symptomatic (NYHA Class II). The decision is made to discontinue lisinopril and initiate sacubitril/valsartan.

Which of the following is the most critical step to ensure patient safety during this medication transition, and what is the underlying pharmacological reason for this precaution?

  1. Administer the first dose of sacubitril/valsartan with the last dose of lisinopril to ensure continuous RAAS blockade and prevent rebound hypertension.
  2. Initiate sacubitril/valsartan at least 36 hours after the last dose of lisinopril to allow for clearance of the ACE inhibitor and reduce the risk of angioedema. (correct answer)
  3. Start a low-dose ARB for 24 hours as a bridge therapy between stopping lisinopril and starting sacubitril/valsartan to prevent acute decompensation.
  4. Check plasma renin activity before starting sacubitril/valsartan to ensure the RAAS is not overly suppressed, which would increase the risk of severe hypotension.
Explanation: The correct answer is B. Concurrent use of an ACE inhibitor (like lisinopril) and a neprilysin inhibitor (sacubitril) is contraindicated due to a significantly increased risk of life-threatening angioedema. Neprilysin breaks down bradykinin, while ACE inhibitors prevent its breakdown. The dual inhibition leads to excessive bradykinin accumulation. A 36-hour washout period is mandatory when switching from an ACE inhibitor to an ARNI to allow the ACE inhibitor to be cleared from the system. A is incorrect because co-administration is dangerous and specifically contraindicated. C is incorrect because a bridge therapy is not required, and the ARB component is already part of the ARNI. The key is the washout period, not adding another drug. D is incorrect because while RAAS status is important for blood pressure, measuring plasma renin activity is not a standard or necessary step, and the primary safety concern during the switch is angioedema, not hypotension.

Question 12

A patient with a history of idiopathic angioedema (not related to any medication) is being considered for HFrEF therapy. Which statement regarding the use of sacubitril/valsartan in this patient is most accurate?

  1. The medication is strictly contraindicated due to any history of angioedema, regardless of the cause.
  2. The medication can be initiated, as the contraindication applies only to angioedema specifically caused by prior ACE inhibitor or ARB therapy.
  3. The medication can be used, but only if the patient is pre-treated with an H1-receptor antagonist to prevent a reaction.
  4. The medication should be avoided, as neprilysin inhibition can exacerbate any predisposition to angioedema by increasing bradykinin levels. (correct answer)
Explanation: The correct answer is D. While the absolute contraindication for sacubitril/valsartan is a history of angioedema related to previous ACE inhibitor or ARB therapy, caution is strongly advised in patients with any history of angioedema. Neprilysin inhibition increases levels of bradykinin, a key mediator of angioedema. In a patient with a known predisposition to angioedema (even idiopathic), using a drug that increases bradykinin levels poses a significant risk of triggering an episode. Therefore, it should generally be avoided. A is too absolute; the formal contraindication is specific to ACEi/ARB-related angioedema. B is a dangerous misinterpretation of the guidelines; while not an absolute contraindication, the risk is high and it should be used with extreme caution, if at all. C is incorrect as pre-treatment is not a standard or validated approach to mitigate this risk.

Question 13

A patient stabilized on sacubitril/valsartan for HFrEF is noted to have a significant increase in their plasma B-type natriuretic peptide (BNP) level on a routine lab draw, though they report no change in symptoms. Their N-terminal pro-B-type natriuretic peptide (NT-proBNP) level has remained stable. What is the most likely explanation for this discrepancy?

  1. The patient is developing subclinical worsening of heart failure that is not yet symptomatic, and the NT-proBNP level will likely rise soon.
  2. The valsartan component of the ARNI is causing a paradoxical increase in BNP release from the ventricles as a compensatory mechanism.
  3. The sacubitril component inhibits the breakdown of active BNP by neprilysin, leading to its accumulation in the plasma, making it an unreliable biomarker. (correct answer)
  4. Laboratory error is the most probable cause, as BNP and NT-proBNP are derived from the same precursor and should always trend together.
Explanation: The correct answer is C. Sacubitril's mechanism of action is to inhibit neprilysin, the enzyme responsible for the degradation of several vasoactive peptides, including the active form, BNP. Therefore, treatment with sacubitril/valsartan leads to an expected increase in plasma BNP levels. In contrast, NT-proBNP is not a substrate for neprilysin and is cleared by other pathways. Consequently, NT-proBNP remains a reliable biomarker for monitoring heart failure status in patients on an ARNI, while BNP becomes unreliable. The stable NT-proBNP suggests the patient is clinically stable. A is less likely given the stable NT-proBNP and lack of symptoms. B is incorrect; the ARB component does not cause a rise in BNP. D is incorrect because while they come from the same precursor, their metabolic pathways differ, which is the key pharmacological point being tested.

Question 14

A patient is prescribed sacubitril as a monotherapy for hypertension without a concurrent angiotensin receptor blocker (ARB) or ACE inhibitor. Which of the following outcomes is most likely to occur as a result of inhibiting neprilysin alone?

  1. A profound and sustained decrease in blood pressure due to unopposed accumulation of natriuretic peptides without any significant adverse effects.
  2. A blunted effect on blood pressure due to compensatory activation of the renin-angiotensin-aldosterone system (RAAS) that is not blocked. (correct answer)
  3. Selective reduction in cardiac preload with no effect on afterload, leading to an isolated improvement in diastolic function.
  4. Severe hyperkalemia resulting from the direct inhibition of potassium channels in the renal collecting duct by sacubitril's active metabolite.
Explanation: The correct answer is B. Neprilysin degrades not only natriuretic peptides but also angiotensin II. Inhibiting neprilysin with sacubitril alone would lead to an accumulation of angiotensin II. This would cause potent vasoconstriction and aldosterone release, counteracting the beneficial vasodilatory and natriuretic effects of the accumulated natriuretic peptides. This is precisely why a neprilysin inhibitor must be co-administered with a RAAS blocker (specifically an ARB, not an ACEI due to angioedema risk). The ARB blocks the effects of the increased angiotensin II, allowing the benefits of natriuretic peptide enhancement to prevail. A is incorrect because the effect would be blunted, not profound. C is incorrect as the peptide effects would influence both preload and afterload, but the main issue is the counter-regulatory RAAS activation. D is incorrect as sacubitril does not directly cause hyperkalemia via this mechanism; hyperkalemia with ARNIs is related to the ARB component's effect on aldosterone.

Question 15

A patient with HFrEF develops symptomatic hypotension after their sacubitril/valsartan dose is titrated up. Their other medications include carvedilol and furosemide. Which of the following is the most appropriate initial management step?

  1. Immediately discontinue the carvedilol, as beta-blockade is the most likely cause of the hypotension.
  2. Reduce or temporarily hold the dose of the diuretic (furosemide) before adjusting the dose of the ARNI. (correct answer)
  3. Switch from sacubitril/valsartan back to an ACE inhibitor, as they are less likely to cause hypotension.
  4. Add a low dose of a mineralocorticoid receptor antagonist (MRA) to help retain sodium and water, thereby increasing blood pressure.
Explanation: The correct answer is B. When hypotension occurs after initiating or up-titrating guideline-directed medical therapy for HF, the first step is often to adjust other medications that can lower blood pressure, particularly diuretics. Reducing the diuretic dose can correct any over-diuresis or volume depletion, potentially allowing the patient to tolerate the target dose of the life-saving ARNI. This approach prioritizes maintaining the neurohormonal blockade agents. A is incorrect because while beta-blockers lower blood pressure, discontinuing them abruptly is undesirable and they are a cornerstone of HF therapy; adjusting diuretics is a less drastic first step. C is incorrect as ARNIs have demonstrated superior outcomes to ACE inhibitors, and switching back would be a therapeutic step backward. Hypotension can also occur with ACEIs. D is incorrect as adding an MRA would be for its mortality benefit, not to manage hypotension, and it can also contribute to hypotension and hyperkalemia.

Question 16

Which of the following correctly distinguishes the primary renal hemodynamic effects of an ARNI from those of an SGLT2 inhibitor in a patient with heart failure?

  1. ARNI causes afferent arteriolar vasodilation, while an SGLT2 inhibitor causes efferent arteriolar vasoconstriction.
  2. ARNI causes predominantly efferent arteriolar vasodilation, while an SGLT2 inhibitor causes predominantly afferent arteriolar vasoconstriction. (correct answer)
  3. Both agents cause efferent arteriolar vasodilation, but the effect of the SGLT2 inhibitor is dependent on ambient glucose levels.
  4. Both agents cause afferent arteriolar vasoconstriction, but the effect of the ARNI is mediated by natriuretic peptides.
Explanation: The correct answer is B. The ARB component of an ARNI blocks angiotensin II at the AT1 receptor, leading to vasodilation of the efferent arteriole, which is preferentially constricted by angiotensin II. This reduces intraglomerular pressure. An SGLT2 inhibitor blocks sodium and glucose reabsorption in the proximal tubule, increasing sodium delivery to the macula densa. This triggers tubuloglomerular feedback, leading to vasoconstriction of the afferent arteriole. Both mechanisms reduce intraglomerular pressure, which is thought to be renoprotective. A is incorrect as the sites and directions of action are swapped. C is incorrect because an ARNI's primary effect is on the efferent arteriole, and an SGLT2 inhibitor's is on the afferent. D is incorrect as neither primarily causes afferent vasoconstriction via natriuretic peptides; the ARNI causes efferent dilation.

Question 17

Beyond its effects on natriuretic peptides, sacubitril's inhibition of neprilysin leads to increased levels of other vasoactive substances. An accumulation of which of the following neprilysin substrates is thought to be the primary cause of the increased risk of angioedema associated with ARNIs?

  1. Bradykinin (correct answer)
  2. Adrenomedullin
  3. Substance P
  4. Angiotensin II
Explanation: When you encounter questions about ARNIs (angiotensin receptor-neprilysin inhibitors) and their side effects, focus on neprilysin's role as a peptidase that breaks down multiple vasoactive substances. Understanding which substrates accumulate and their clinical consequences is key to predicting adverse effects. Neprilysin normally degrades bradykinin, a potent vasodilator that also increases vascular permeability. When sacubitril inhibits neprilysin, bradykinin levels rise significantly. This accumulation is particularly problematic because bradykinin directly triggers the cascade leading to angioedema—it causes vasodilation, increases capillary permeability, and promotes fluid extravasation into tissues, especially around the face, lips, and airway. The risk is amplified when ARNIs are combined with ACE inhibitors, since ACE inhibitors also increase bradykinin by blocking its conversion to inactive metabolites. Choice B (adrenomedullin) is incorrect because while neprilysin does degrade adrenomedullin, its accumulation primarily causes vasodilation and natriuresis, not angioedema. Choice C (substance P) is wrong—though substance P can theoretically contribute to vascular permeability, bradykinin is the dominant player in ARNI-associated angioedema. Choice D (angiotensin II) is incorrect because ARNIs actually block angiotensin II receptors and don't significantly affect its levels through neprilysin inhibition. Remember this pattern: when evaluating ARNI side effects, bradykinin accumulation explains the serious complications (angioedema), while natriuretic peptide preservation explains the therapeutic benefits. This dual mechanism is what makes ARNIs both effective and potentially dangerous.

Question 18

A 70-year-old patient with HFrEF and T2DM is managed with metformin, sacubitril/valsartan, and carvedilol. An SGLT2 inhibitor is added. The patient is counseled on the risk of euglycemic diabetic ketoacidosis (DKA). Which of the following situations would most significantly increase this patient's risk of developing euglycemic DKA?

  1. Experiencing a period of acute illness, such as influenza with poor oral intake. (correct answer)
  2. Consuming a high-carbohydrate meal before a strenuous workout.
  3. Missing a single dose of their metformin.
  4. A slight, asymptomatic increase in serum creatinine.
Explanation: When you encounter SGLT2 inhibitor questions, focus on understanding euglycemic DKA—a serious condition where ketoacidosis occurs without significantly elevated glucose levels. SGLT2 inhibitors increase ketone production while lowering glucose, creating this dangerous scenario. Acute illness with poor oral intake (A) creates the perfect storm for euglycemic DKA. During illness, your body releases stress hormones that promote ketone production while simultaneously reducing insulin effectiveness. Poor oral intake means inadequate carbohydrate consumption, forcing the body to break down fat for energy—further increasing ketones. The SGLT2 inhibitor compounds this by continuing to lower glucose levels while promoting ketogenesis. This combination of metabolic stress, reduced food intake, and ongoing SGLT2 inhibition dramatically increases euglycemic DKA risk. A high-carbohydrate meal before exercise (B) would actually be protective, as carbohydrates provide glucose and reduce the need for fat breakdown. Missing one metformin dose (C) has minimal acute impact since metformin doesn't directly affect ketone metabolism and has a long half-life. A slight creatinine increase (D) might warrant monitoring but doesn't acutely precipitate ketoacidosis—SGLT2 inhibitors often cause mild, reversible creatinine elevations. Remember this pattern: SGLT2 inhibitor + any condition that promotes ketone production (illness, fasting, dehydration, surgery) = high euglycemic DKA risk. Always counsel patients to temporarily discontinue SGLT2 inhibitors during acute illness, especially with poor oral intake, vomiting, or dehydration.

Question 19

In the context of myocardial energetics, a key proposed benefit of SGLT2 inhibitors in heart failure is the shift of substrate utilization in the heart. This involves a relative increase in the oxidation of which fuel source by cardiomyocytes?

  1. Glycogen stores
  2. Long-chain fatty acids
  3. Lactate
  4. Ketone bodies (correct answer)
Explanation: The correct answer is D. The failing heart is often described as an 'engine out of fuel,' with impaired metabolism of its usual primary fuel, fatty acids. SGLT2 inhibitors induce a mild, chronic state of hyperketonemia. Ketone bodies (like beta-hydroxybutyrate) are a highly efficient fuel source for the heart, producing more ATP per unit of oxygen consumed compared to fatty acids. It is hypothesized that this metabolic shift to ketone oxidation improves myocardial efficiency and function, contributing to the cardiovascular benefits of the drug class. A, B, and C are all cardiac fuel sources, but the specific shift promoted by SGLT2 inhibitors that is thought to be beneficial is away from fatty acids (B) and towards ketones (D).

Question 20

The landmark PARADIGM-HF trial demonstrated the superiority of sacubitril/valsartan over enalapril in patients with HFrEF. The primary endpoint was a composite of death from cardiovascular causes or first hospitalization for worsening heart failure. What is the accepted pharmacological explanation for this superior efficacy?

  1. The simultaneous inhibition of neprilysin and blockade of the RAAS provides benefits from natriuretic peptide enhancement that are not achieved by RAAS inhibition alone. (correct answer)
  2. Sacubitril/valsartan provides more potent and complete blockade of the AT1 receptor compared to enalapril's inhibition of ACE.
  3. Sacubitril/valsartan causes a greater reduction in heart rate and blood pressure, which are the primary drivers of improved outcomes.
  4. Enalapril has a higher incidence of cough, leading to poor adherence and consequently worse outcomes in the comparator arm.
Explanation: When you encounter questions about heart failure medications, focus on understanding the specific mechanisms of action and how they translate to clinical benefits. The PARADIGM-HF trial is a landmark study that changed heart failure treatment guidelines. Sacubitril/valsartan (Entresto) is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI). The key to its superior efficacy lies in its dual mechanism: it blocks the renin-angiotensin-aldosterone system (RAAS) through valsartan's AT1 receptor antagonism while simultaneously inhibiting neprilysin through sacubitril. Neprilysin is an enzyme that breaks down beneficial natriuretic peptides (BNP, ANP). By blocking neprilysin, sacubitril allows these peptides to accumulate, promoting vasodilation, natriuresis, and diuresis. This dual approach provides the proven benefits of RAAS blockade plus additional cardiovascular protection from enhanced natriuretic peptide activity that ACE inhibitors alone cannot achieve. Option B is incorrect because valsartan doesn't provide "more potent" AT1 blockade than enalapril's ACE inhibition—these are simply different mechanisms of RAAS interruption with similar efficacy profiles. Option C misses the primary mechanism; while hemodynamic effects occur, the superior outcomes stem from the neprilysin inhibition component, not greater blood pressure reduction. Option D incorrectly attributes the difference to adherence issues with enalapril's cough side effect, but this wasn't the explanation for PARADIGM-HF's results. Remember: ARNI represents a paradigm shift because it's the first medication to simultaneously enhance a protective pathway (natriuretic peptides) while blocking a harmful one (RAAS).